BioCentury
ARTICLE | Clinical News

TSR-011: Preliminary Phase I/IIa data

October 28, 2013 7:00 AM UTC

Preliminary data from the dose-escalation Phase I portion of an open-label Phase I/IIa in 17 evaluable patients showed that TSR-011 for 8 weeks led to a partial response or stable disease in 11 patien...